Table I.
MAGE family member | Affymetrix ID | Lymph node status | HR | 95% CI | P-value |
---|---|---|---|---|---|
MAGEA5 | 214642_x_at | Positive | 1.24b | 1.00–1.53b | 0.0447b |
Negative | 0.90 | 0.76–1.06 | 0.2129 | ||
MAGEA8 | 210274_at | Positive | 1.22 | 0.99–1.52 | 0.0646 |
Negative | 0.85 | 0.71–1.03 | 0.0946 | ||
MAGEB4 | 207580_at | Positive | 1.18 | 0.95–1.48 | 0.1385 |
Negative | 0.87 | 0.72–1.06 | 0.1809 | ||
MAGEB6 | 1552858_at | Positive | 0.78 | 0.60–1.00 | 0.0515 |
Negative | 0.55a | 0.33–0.91a | 0.0188a | ||
MAGEB18 | 1552913_at | Positive | 0.84 | 0.65–1.09 | 0.1869 |
Negative | 1.47 | 0.98–2.21 | 0.0601 | ||
MAGEC3 | 216592_at | Positive | 1.20 | 0.98–1.48 | 0.0810 |
Negative | 0.85 | 0.71–1.01 | 0.0640 | ||
MAGED2 | 213627_at | Positive | 0.79a | 0.65–0.96a | 0.0200a |
Negative | 0.82a | 0.68–0.99a | 0.0400a | ||
MAGED3 | 205028_at | Positive | 0.81a | 0.67–0.99a | 0.0390a |
Negative | 1.10 | 0.93–1.30 | 0.2800 | ||
MAGED4 | 221261_x_at | Positive | 1.24b | 1.02–1.51b | 0.0290b |
Negative | 1.27b | 1.07–1.51b | 0.0062b | ||
MAGEE1 | 1556047_s_at | Positive | 0.81 | 0.62–1.04 | 0.1013 |
Negative | 0.79 | 0.54–1.17 | 0.2400 | ||
MAGEE2 | 1553254_at | Positive | 1.23 | 0.95–1.58 | 0.1096 |
Negative | 0.57a | 0.33–0.98a | 0.0376a | ||
MAGEF1 | 218176_at | Positive | 0.75a | 0.61–0.93a | 0.0094a |
Negative | 1.26b | 1.07–1.50b | 0.0063b | ||
MAGEH1 | 218573_at | Positive | 1.30b | 1.04–1.62b | 0.0185b |
Negative | 0.91 | 0.75–1.11 | 0.3438 | ||
MAGEL2 | 219894_at | Positive | 1.08 | 0.88–1.31 | 0.4600 |
Negative | 0.83a | 0.69–1.00a | 0.0464a |
P<0.05 was considered to indicate a statistically significant difference.
High mRNA expression levels associated with improved RFS
high mRNA expression levels associated with worse RFS. Total patients assigned a lymph node status, n=3,718; lymph node-positive patients, n=1,459; lymph node-negative patients, n=2,259, analyzed by ANOVA. CI, confidence interval; HR, hazard ratio; MAGE, melanoma-associated antigen; RFS, relapse-free survival.